Dual-product commercial story at $500M+ revenue pace, but a guidance cut and XPHOZAH reimbursement loss test whether IBSRELA alone can carry the long-term thesis

Ardelyx is a commercial-stage biopharmaceutical company with two approved targeted drugs: IBSRELA for irritable bowel syndrome and XPHOZAH for high phosphorus levels in dialysis patients, though XPHOZAH has recently lost a key reimbursement appeal.

Ardelyx has two approved NHE3 inhibitors on the market, IBSRELA for IBS and XPHOZAH for dialysis-related hyperphosphatemia, generating record quarterly revenue, but a Q2 2026 guidance cut and a lost reimbursement appeal for XPHOZAH introduce real uncertainty. The thesis resolves on whether IBSRELA sustains its growth trajectory to reach the $1B long-term target while XPHOZAH stabilizes under unfavorable payer conditions. Payer utilization management pressures on IBSRELA, and the structural reimbursement disadvantage now locked in for XPHOZAH, are the primary risks to that scenario.